Webinar:

Accelerating vaccine development webinar

Sponsored by: Watson-Marlow Fluid Technology Group

Focused on:

  • Biologics
  • Vaccine Development

Date: 25 September

31

Time: 10AM BST

Cobra Biologics and Watson-Marlow Fluid Technology Group discuss the challenges of vaccine production

Join our webinar to hear from Cobra Biologics’ Technical Director, Tony Hitchcock, and from Watson-Marlow Fluid Technology Group’s (WMFTG) Peter Birch and Dr Sade Mokuolu, as they discuss the strategies for vaccine production, whilst maintaining critical quality standards.

This webinar will discuss:

• The vaccines research landscape
• Learnings from previous epidemics including Ebola, SARS and MERS
• Progress made so far in the COVID-19 pandemic
• The challenges of vaccine development including the skills, technology and resources needed
• A particular focus on the challenges of scaling up production for a global pandemic

Vaccine development is a complex and time-consuming process and, even when a safe and effective vaccine is discovered, rapidly scaling up to produce sufficient doses to overcome a global pandemic is a challenge in itself. Drug companies are dependent on high-quality bioprocessing equipment that satisfies regulatory requirements and delivers consistent product quality with critical product validation. This is essential to reliably and efficiently scale up medicines.

Even when a safe and effective vaccine is discovered, producing sufficient doses, initially for clinical trials and then for widespread distribution, is a challenge in itself. Biotherapeutics require tightly controlled conditions for their production and it is difficult to maintain these specific conditions when scaling up from a research lab to global production, as required in a pandemic such as coronavirus. There is also the added time pressure of creating and scaling up a vaccine as quickly as possible.

As the pressure mounts, drug companies are dependent on high-quality bioprocessing equipment that satisfies regulatory requirements and delivers consistent product quality with critical product validation. This is essential to reliably and efficiently scale up medicines.

Join our webinar to hear from global experts on the challenges associated with manufacturing of vaccines and the progress being made.

Register for the webinar today.

Presented by

Peter Birch,

Global biopharmaceutical expert at Watson-Marlow

Peter Birch is Global Business Development Manager for Biopharmaceutical Equipment at Watson-Marlow. Peter has extensive experience developing strategic relationships and collaborating with customers to build effective alliances, having worked for Thermofisher Scientific, Hans Buch+Co, Sartorious Stedim Biotech and Copenhagen University Hospital.

Tony Hitchcock,

Technical Director, Cobra Biologics

Tony Hitchcock is the Technical Director at Cobra Biologics, specialising in the development of cell and gene therapy. As a founding staff member of Cobra, Tony has been responsible for the development of much of Cobra’s manufacturing technologies in the field of DNA and virus production and was involved in one of the first licenced gene therapy projects. Additionally, Tony is currently a member of the BIA Science and Innovation Advisory Committee (SIAC) and of industrial advisory boards for Aston and Loughborough Universities.

Dr Sade Mokuolu,

Global Regulatory and Validation Services Lead at Watson-Marlow

Dr Sade Mokuolu is Global Regulatory and Validation Services Manager at Watson-Marlow. She is a co-author on Biophorum’s Single-Use user requirement (SUUR) guide and has published a number of articles on validation & qualification of single-use systems. She has presented at international conferences on behalf of the Bio-Process Systems Alliance (BPSA), as well as delivering single-use validation training to the Australian regulatory agency (TGA), and European GMP inspectors.

Key Learning Objectives

  • Learnings from previous epidemics including Ebola, SARS and MERS
  • Progress made so far in the COVID-19 pandemic
  • An in-depth look at Cobra Biologics’ platform technology and vaccine manufacturing programme
  • A particular focus on the challenges of scaling up production for a global pandemic

Audience

  • Production Managers
  • Technical Directors
  • Research & Development Team Leaders